Clinical AI for better patient outcomes

Recent advances in artificial intelligence have enabled a new generation of companies and products that are poised to change healthcare forever. From drug discovery to early disease detection, AI is shaping a future where care is personalized, preemptive, and affordable.

Biocogniv enables a key part of this future by combining laboratory medicine, state-of-the-art AI, and evidence-based acute care, to reduce preventable hospital deaths, morbidities, and cost of care.



Data Scientist

Kylin Willis

Kylie Willis is a data scientist who graduated Cum Laude from the University of Vermont, earning recognition with the Biomedical Engineering Program award. At Biocogniv, she applies her biomedical engineering background to build our data science platform, from lab data harmonization pipelines to AI models.

Data Scientist

Tucker Paron, MS

Tucker holds a Master of Science degree in Complex Systems and Data Science from the University of Vermont, where he applied advanced machine learning and AI to wearables research. While at UVM he also competed on the Men’s Varsity Soccer team.

Senior Software Engineer

Bennett Siegel

Bennett is a computer scientist from the University of Vermont, with nearly a decade of experience as software engineer. Prior to Biocogniv, he was a Java engineer at Dealer.com, Root Level, and Green Mountain Power.

Operations and Compliance Manager

Alessandra Conner, OD

Alessa received her OD from the New England College of Optometry in Boston. She has provided care in community health settings, hospital settings and private practices, and through these experiences she developed a passion for improved patient outcomes. Alessa joins with a background and interest in healthcare compliance management.


Jeremy Huckins, PhD

Jeremy received his PhD in Experimental and Molecular Medicine from Dartmouth College, where he also led NIH-funded research projects as a post-doc. His publications focus on the application of Machine Learning to biomedical problems, and have generated over 3,000 citations. Prior to Dartmouth, Jeremy performed research at Harvard Medical School.

Medical Director

Christos Colovos, MD PhD FACS

Dr. Colovos is an ICU doctor and acute care surgeon trained at Cedars-Sinai, with a PhD in computational biochemistry from UCLA. His work has been cited more than 4,000 times, and covers a broad range of topics, from immunology to novel CAR T-Cell therapies for cancer and computational protein structure.

COO, Head of Compliance

Jabez Boyd

A senior executive with cross-functional experience across multiple technology startups, Jabez was a sales executive at LoopNet Inc (IPO), VP of Corporate Development at MyWebGrocer (acq), and VP of Sales at EpikOne (acq).


Steve Wallace

Steve was a VP of Technology at Goldman-Sachs, where he joined after the successful acquisition of Dwight Asset Management ($75B+ in assets under management). Since then, he has taken on software architect roles at Green Mountain Power, iSystems, and Asure.

CEO, Founder

Artur Adib, PhD

Artur received his PhD from Brown University and was a faculty member at the National Institutes of Health, with peer-reviewed publications ranging from computer science to biophysics and quantum mechanics. He was part of the founding team at Amazon-backed aerospace company Beta Technologies, pre-IPO engineer at Twitter, and principal engineer at Magic Leap.

Strategic advisory board

Ben Miller

Ben Miller retired in 2019 from Labcorp (NYSE:LH) where he was EVP and COO. In his 34-year career at Labcorp, Ben oversaw the company's core business units, managed care functions, sales and marketing, hospital and health system organizations, and Esoteric Business Units including Endocrine Sciences, National Genetics Institute, Monogram Biosciences, Integrated Oncology, Integrated Genetics, Code Cellmark, Identity Testing and more.

Leo Grady, PhD

Leo is a medtech executive with decades of experience in the development and commercialization of advanced AI, diagnostic, and digital health technologies. During his tenure as CEO of Paige.AI, Leo led the first-ever FDA approval for an AI product in pathology, raising $195M of investment capital and growing both company valuation and employee count by more than 10X. Prior to joining Paige, Leo was the SVP of Engineering for HeartFlow, where he led full stack technology and product development efforts for HeartFlow’s cardiovascular IP portfolio. He is now CEO-in-Residence at Breyer Capital.

Jonathan Hirsch

Jonathan is a company founder, investor, and advisor at the intersection of healthcare, life sciences, and data. As a founder of Syapse, he defined and implemented a vision for transforming cancer care through precision medicine and real world evidence, and catalyzed national cancer data sharing networks, including serving on the White House Cancer Moonshot Data Sharing Working Group. Jonathan presently serves on the advisory boards of companies including Freenome, Viz.AI, and Paige.AI, and is an active investor and partner with Kleiner Perkins seed fund, Rebel Fund, and others.

Sarah Kalil

Sarah was COO of T2 Biosystems (NASDAQ:TTOO) and helped the company go public to bring sepsis diagnostic devices to market. A seasoned medtech executive and advisor, Sarah has helped companies like Binx Health and Hologic receive FDA clearance for their diagnostic products, and is presently the CEO and co-founder of Series B med device company CoreMap.

Medical advisory board

Myla Lai-Goldman, MD

Dr. Lai-Goldman spent more than 18 years at Labcorp (NYSE:LH), the last 10 years as Executive Vice President, Chief Medical and Chief Scientific Officer, after which she co-founded GeneCentric Therapeutics. During her tenure at LabCorp, she led all clinical, scientific and medical activities, including the introduction of more than 400 clinical assays. She is a recognized speaker and author on understanding and overcoming the barriers to test adoption. Dr. Lai-Goldman presently serves on the board of several public and private companies, including West Pharmaceutical (NYSE:WST) and Akoya Biosciences (NASDAQ:AKYA).

Frank Peacock, MD FACEP FACC

Frank Peacock is a thought leader in biomarkers for acute care, with over 600 peer-reviewed publications. He was formerly Vice Chair of Research at Cleveland Clinic, and is presently Professor of Emergency Medicine, Associate Chair, and Research Director for the department of Emergency Medicine at the Baylor College of Medicine.

Joshua Tamayo-Sarver, MD PhD FACEP

Joshua Tamayo-Sarver is Vice President of Innovation at Vituity, one of the largest employers of doctors in the country and responsible for staffing 500 care facilities. He works clinically as a staff physician in the Emergency Department at Good Samaritan Hospital in San Jose, California, where he is the past Department Vice-Chair and Director of Quality Improvement.